On April 12, Friends of Cancer Research held a briefing on Capitol Hill on the topic of Breakthrough Therapy Designation: Successes, Lessons Learned and Future Strategies. Through the breakthrough therapy program, which followed the passage of the Food and Drug Administration Safety and Innovation Act (FDASIA) in 2012, a new drug may be designated as […]
In our previous blog post opening this year’s Global Asbestos Awareness Week, we mentioned that prevention of mesothelioma can take several different shapes. Avoiding exposures to asbestos is one such method. However, while theoretically valid, in reality this method falls short in accomplishing this goal because asbestos is showing no signs of going away. It […]
Just today, we learned that Verastem, a biotech company that has previously done research in mesothelioma, has now embarked on several new projects.
In the news, announced in a press release, the company lists several projects, including this one:
Clinical Collaboration with Pfizer and Merck KGaA to Evaluate Combination of VS-6063 and Avelumab in Ovarian Cancer –In March […]
We are pleased to announce the funding of five new mesothelioma research projects by the Meso Foundation. To date the Meso Foundation has funded 99 projects amounting to over $9.4 million awarded toward mesothelioma research.
The Meso Foundation’s research program follows a rigorous peer-review system modeled after that of the National Institutes of Health. Each year, […]
In the latest iteration of its budget bill, Congress included $50 million for the Department of Defense’s (DoD) Peer Reviewed Cancer Research Program (PRCRP). The bill will be voted on in the House on Friday, and in the Senate shortly thereafter.
If the bill does pass, this level of funding will be consistent with funding for […]